Press |

Wetenschappelijke publicaties DUOS 2018

De output binnen DUOS is groot. Een greep uit de wetenschappelijke publicaties die verschenen naar aanleiding van DUOS activiteiten in 2018 treft u onderstaand.


  1. Eur Urol Focus. 2018 Sep;4(5):694-701. doi: 10.1016/j.euf.2016.09.008. Epub 2016 Oct 13. Differences in Trial and Real-world Populations in the Dutch Castration-resistant Prostate Cancer Registry.(CAPRI)
  2. Clin Cancer Res. 2018 Feb 1;24(3):541-546. doi: 10.1158/1078-0432.CCR-17-2336. Epub 2017 Nov 17. Influence of Enzalutamide on Cabazitaxel Pharmacokinetics: a Drug-Drug Interaction Study in Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients.
  3. Eur Urol. 2018 Feb;73(2):149-152. doi: 10.1016/j.eururo.2017.08.022. Epub 2017 Sep 13. Response Rate to Chemotherapy After Immune Checkpoint Inhibition in Metastatic Urothelial Cancer.
  4. Clin Nucl Med. 2018 Jan;43(1):9-16. doi: 10.1097/RLU.0000000000001904. 223Ra Therapy in Patients With Advanced Castration-Resistant Prostate Cancer With Bone Metastases: Lessons from Daily Practice.
  5. Urol Oncol. 2018 Sep;36(9):413-422. doi: 10.1016/j.urolonc.2017.10.014. Epub 2017 Nov Neoadjuvant treatment for muscle-invasive bladder cancer: The past, the present, and the future.
  6. Urol Oncol. 2018 Sep;36(9):423-431. doi: 10.1016/j.urolonc.2018.01.014. Epub 2018 Mar .recommendations for follow-up of muscle-invasive bladder cancer patients: A consensus by the international bladder cancer network.
  7. Contemp Clin Trials Commun. 2018 Feb 28;9:121-129. doi: 10.1016/j.conctc.2018.01.007. eCollection 2018 Mar. Reduce bladder cancer recurrence in patients treated for upper urinary tract urothelial carcinoma: The REBACARE-trial.
  8. BJU Int. 2018 Dec;122(6):978-985. doi: 10.1111/bju.14238. Epub 2018 Apr 27. The World Health Organization 1973 classification system for grade is an important prognosticator in T1 non-muscle-invasive bladder cancer.
  9. Int J Cancer. 2019 Mar 15;144(6):1453-1459. doi: 10.1002/ijc.31833. Epub 2018 Sep 24. Superior efficacy of neoadjuvant chemotherapy and radical cystectomy in cT3-4aN0M0 compared to cT2N0M0 bladder cancer.
  10. Clin Oncol. 2018 Feb 20;36(6):572-580. doi: 10.1200/JCO.2017.75.2998. Epub 2017 Dec 22. Circulating Tumor Cell Number as a Response Measure of Prolonged Survival for Metastatic Castration-Resistant Prostate Cancer: A Comparison With Prostate-Specific Antigen Across Five Randomized Phase III Clinical Trials.
  11. Eur Urol. 2018 Nov 26. pii: S0302-2838(18)30856-X. doi: 10.1016/j.eururo.2018.11.002. [Epub ahead of print] PD-L1 Antibody Comparison in Urothelial Carcinoma.
  12. J Clin Oncol. 2018 Jun 1;36(16):1579-1587. doi: 10.1200/JCO.2017.76.9562. Epub 2018 Mar 28. Health-Related Quality-of-Life Analysis From KEYNOTE-045: A Phase III Study of Pembrolizumab Versus Chemotherapy for Previously Treated Advanced Urothelial Cancer.

© 2019, Stichting DUOS, redactie en teksten: Kuip&Ko, website: sbddesign.nldisclaimer   |   log in